Skip to main content

Testicular germ cell tumours in Iceland: A nationwide clinicopathological study

Buy Article:

$51.00 plus tax (Refund Policy)

Abstract:

Agnarsson BA, Gudbjartsson T, Einarsson GV, Magnusson K, Thoroddsen A, Bergthorsson JT, Amundadottir L, Barkardottir RB, Björnsson J. Testicular germ cell tumours in Iceland. A nationwide clinicopathological study. APMIS 2006;114:779–83.

The purpose of this study was to examine the pathology of all germ cell tumours of the testis diagnosed in Iceland 1955–2002. A total of 214 patients were included in the study. The current age-standardized incidence was found to be 6.1 per 100,000 and had increased almost fourfold during the study period. Seminoma was diagnosed in 55% of cases. Non-seminomas were diagnosed in 45%, and these were further classified as mixed germ cell tumours (33%), embryonal carcinoma (8%), teratoma (3%), and yolk sac tumour (n=1). The mean age at diagnosis was significantly higher for the seminomas than the non-seminomas (38 years versus 29 years) (p<0.001) and the non-seminomas were diagnosed at a significantly higher stage than the seminomas (p<0.001). Thus, in seminoma patients the tumour was localized to the testis (stage I) in 81% of cases, in 17% of patients the tumour had spread to the lymph nodes (stage II or III), and only 2% had extranodal metastasis at diagnosis (stage IV). In contrast, in the non-seminoma patients, the tumours were found to be stage I in 56%, stage II or III in 24%, and stage IV in 20% of cases. No significant difference in staging was found between non-seminoma subtypes. Identification of necrosis or vascular invasion was significantly associated with metastatic disease at diagnosis (p=0.002). During the study period a significant increase in stage I tumours was found as well as a decrease in the size of the tumours.

Keywords: Testicular tumours; epidemiology; germ cell tumours; pathology; staging

Document Type: Research Article

DOI: https://doi.org/10.1111/j.1600-0463.2006.apm_468.x

Affiliations: 1: Urology and 2: Oncology, Landspitali-University Hospital, 3: Decode Genetics, Reykjavik, and 4: Pathology,

Publication date: 2006-11-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more